Used in cancer immunotherapy to enhance anti-tumor immune responses by blocking the ENTPD1 (CD39) enzyme, which plays a key role in suppressing immune activity within the tumor microenvironment. By inhibiting CD39, this antibody helps prevent the breakdown of extracellular ATP into adenosine, thereby maintaining high levels of ATP that stimulate immune activation and dendritic cell recruitment. It also reduces immunosuppressive adenosine accumulation, which can otherwise inhibit T cell and natural killer cell function. TTX-030 is being investigated in clinical trials, often in combination with other immunotherapies like PD-1 inhibitors, to improve outcomes in solid tumors and hematologic malignancies. Its application represents a promising approach in modulating the purinergic signaling pathway to support immune-mediated tumor destruction.